Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study

A tyrosine kinase inhibitor (TKI) with combination of intensive chemotherapy achieves high response rate in the treatment of Ph+ ALL. Ponatinib is a more potent BCR-ABL inhibitor than other TKIs.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Koji Sasaki, Hagop Kantarjian, Deborah Thomas, Farhad Ravandi, Maria Khouri, Jorge Cortes, Naveen Pemmaraju, Tapan Kadia, Nicholas Short, Ghayas Issa, Rebecca Garris, Gal Moore, Vicky Jeanis, Guillermo Garcia-Manero, Gautam Borthakur, William Wierda, Susa Source Type: research